NEPHROPLUS2025-10-012025-12-31NEPHROPLUS2025-04-012025-12-31NEPHROPLUS2025-10-012025-12-31in-capmkt:OtherExpenses1MemberNEPHROPLUS2025-10-012025-12-31in-capmkt:OtherExpenses2MemberNEPHROPLUS2025-10-012025-12-31in-capmkt:OtherExpenses3MemberNEPHROPLUS2025-04-012025-12-31in-capmkt:OtherExpenses1MemberNEPHROPLUS2025-04-012025-12-31in-capmkt:OtherExpenses2MemberNEPHROPLUS2025-04-012025-12-31in-capmkt:OtherExpenses3MemberNEPHROPLUS2025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1NEPHROPLUS2025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2NEPHROPLUS2025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1NEPHROPLUS2025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2NEPHROPLUS2025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1NEPHROPLUS2025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares544647NEPHROPLUSNOTLISTEDINE428V01029Nephrocare Health Services LimitedMain BoardEquity2025-04-012026-03-312026-02-102026-01-30INRMillionsQuarterlyThird quarterSingle segmentHealthcare2026-02-1019:30:002026-02-1020:40:002025-10-012025-12-31UnauditedConsolidated259729000033160000263045000058517000000431030000596000002186100009724400002266850000363600000036360000093940000-527400004120000003224000000000322400000157400003381400003224000000338140000020068000023.433.35003.433.35Notes : <BR> 1. The above consolidated financial results of Nephrocare Health Services Limited (formerly Nephrocare Health Services Private Limited)('the Company') and its subsidiaries (Company and its subsidiaries together referred to as “the Group”) for the quarter and nine months ended 31 December 2025, have been prepared in accordance with the Indian Accounting Standard (referred to as 'Ind AS') 34 - Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and in terms of Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. <BR> <BR> 2. These consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 10 February 2026. The Statutory auditors of the Company have conducted a 'Limited Review' of the consolidated financial results in accordance with Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations') and have issued an unmodified review report thereon. <BR> <BR> <BR> 3. The consolidated financial results include the results of the following entities: <BR> Holding Company <BR> Nephrocare Health Services Limited (formerly Nephrocare Health Services Private Limited) <BR> Subsidiary companies <BR> Nephrocare Health Services Central Asia FE LLC <BR> Nephrocare Health Services Nepal Private Limited <BR> Nehrocare Health Services International Pte Ltd <BR> Nephrocare Health Services Saudi Arabia Company <BR> Nephro Plus Kidney Services Company <BR> Nephrocare Health Care Services, Philippines Inc. <BR> Anram Medical Group Inc. <BR> Cadiz Dialysis Hub Inc. <BR> Dialysis Asia and Patient Care Center Inc. <BR> People’s Center For Hemodialysis Care Inc. <BR> Curis Hemodialysis Clinic Inc. <BR> Mega Health Dialysis Center Inc. <BR> Universe Dialysis and Kidney Care Centre Inc. <BR> St. Margareth Dialysis and Biocare Centre Inc. <BR> Medical Experts Group and Associates Inc. <BR> Curis Cavite Renal Corporation <BR> Renal Therapy Solutions, Inc. <BR> Rizal Dialysis and Wellness Centre OPC <BR> Bioregen Hemo Center Inc. <BR> Carmona Dialysis System Inc. <BR> Infini Care Health Systems Inc. <BR> Kolff Dialysis Inc. <BR> AIZ Hemodialysis Centre Inc. <BR> Nephro Alliance Ventures Inc. <BR> <BR> 4. The Group is primarily engaged in business of providing dialysis and sale of related healthcare services and products which is considered to be the only reportable segment as per Ind AS 108, 'Operating Segments'. <BR> <BR> 5.Geographical segment <BR> <BR> The business of providing dialysis and sale of related healthcare services and products are managed on a worldwide basis. The geographic information analyses the Group’s revenue by the Company’s country of domicile (i.e. India) and outside India. The revenue from operations by geographical location is presented below <BR> <BR> Geographical segment Quarter Ended Nine months ended Year ended <BR> 31 December 2025 30 September 2025 31 December 2024 31 December 2025 31 December 2024 31 March 2025 <BR> India 1,478.42 1,450.56 1,302.02 4,321.24 3,783.36 5,155.02 <BR> Outside India 1,118.87 1,006.62 670.55 3,011.06 1,582.83 2,403.10 <BR> <BR> <BR> 6. The figures for the preceding quarter ended 30 September 2025 and corresponding quarter and nine months ended 31 December 2024, as reported in these consolidated financial results, have been approved by the Company's Board of Directors but have not been audited or reviewed by the statutory auditors. This is pursuant to the requirement of submitting quarterly consolidated financial results becoming applicable to the Company with effect from the quarter ended 31 December 2025 pursuant to the listing of its equity shares on BSE Limited ('BSE') and National Stock Exchange of India Limited ('NSE'). The Company's equity shares were listed on the BSE and NSE on 17 December 2025. Hence, this is the first statement of consolidated financial results being prepared and submitted in compliance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended. <BR> <BR> 7. During the quarter ended 31 December 2025, the Company completed an initial public offering (IPO) of 18,943,020 equity shares with a face value of Rs. 2 each. The issue comprised a fresh issue of 7,689,918 equity shares and an offer for sale of 11,253,102 equity shares. The fresh issue included 7,609,118 equity shares issued at an issue price of Rs. 460 per share and 80,800 equity shares issued to employees of the Company at a discounted issue price of Rs. 419 per share. <BR> <BR> 8. On 21 November 2025, the Government of India notified the four Labour Codes - The Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour and Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to the changes in regulations. The Company has assessed and accounted the incremental impact of these changes on the basis of actuarial opinion obtained and the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. The Company continues to monitor the finalization of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. <BR> <BR> 9. During the nine months ended 31 December 2025 and the quarter ended 30 September 2025, the Company incurred interest expense on financial liabilities measured at fair value through profit or loss (FVTPL) aggregating to Rs.371.89 million. The said item is non-cash and non-recurring nature and the impact has been presented under “Finance costs” in the Statement of Consolidated Financial Results. <BR> <BR> <BR> 10. The results for quarter and nine months ended 31 December 2025, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: nseindia.com) and on the Company's website (URL: https://nephroplus.com/investors). <BR> <BR> <BR> *Earnings per equity share is not annualised for the quarters and nine months ended. <BR> 2025-04-012025-12-31UnauditedConsolidated733230000012944000074617400001671590000001258610000570620000648220000267015000068191900006425500000642550000267790000-89940000177850000046470000000004647000001270700005917700004647000000591770000020068000025.325.03005.325.03Healthcare professional fees305880000Hospital fees200870000Other expenses465690000Healthcare professional fees828620000Hospital fees587550000Other expenses1253980000Remeasurement gains/(loss) on defined benefit plans-1720000Tax on remeasurement gains/(loss) on defined benefit plans430000-1290000Remeasurement gains/(loss) on defined benefit plans-410000Tax on remeasurement gains/(loss) on defined benefit plans100000-31000000Exchange differences on translating financial statements of foreign operations1703000017030000Exchange differences on translating financial statements of foreign operations1273800001273800000015740000127070000